WithdrawnNot Applicable

Ruxolitinib in Combination With Autotransplant

Stopped: no enrollments

0Started 2015-05

Plain-language summary

To determine the safety of the approach of giving RUXOLITINIB before and after an autologous stem cell transplant, as measured by graft failure or death.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Red cell transfusion dependency
✓. unfavorable Karyotype
✓. platelet count \<100 x 109/L
✓. symptomatic splenomegaly
✓. PB blasts \> 1%
✓. Blasts in PB \<20% prior to study enrollment
✓. No available suitable matched related (6/6 or 5/6) or unrelated donor (8/8 or 7/8 allele matched) or unwilling or unable to pursue allogeneic stem cell transplant
✓. WBC \<50,000/ml at screening

What they're measuring

Safety of combining ruxolitinib with autologous HSCT measured by graft failure or death

Timeframe: 2 years

Trial details

NCT IDNCT02469974

SponsorMarina Kremyanskaya

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-08

View on ClinicalTrials.gov More Myelofibrosis trials